Atuveciclib (BAY-1143572)

Cell experiment:

HeLa human cervical tumor cells (CCL-2) and MOLM-13 human acute myeloid leukemia cells (ACC 554) are propagated under the suggested growth conditions in a humidified 37°C incubator. Proliferation assays are conducted in 96-well plates at densities of 3000 (HeLa) and 5000 (MOLM-13) cells per well in the growth medium containing 10 % fetal calf serum (FCS). Cells are treated in quadruplicate with serial dilutions of test compounds (e.g., Atuveciclib (BAY-1143572)) for 96 h. Relative cell numbers are quantified by crystal violet staining (HeLa) or CellTitre-Glo Luminescent Cell Viability Assay (MOLM-13). IC50 values are determined by means of a four-parameter fit on measurement data which are normalized to vehicle (DMSO) treated cells (=100 %) and measurement readings taken immediately before compound exposure (=0 %)[1].

Animal experiment:

Mice and Rats[1]For the acute myeloid leukemia (AML) mouse model, 2×106 MOLM-13 human AML cells are inoculated subcutaneously to the left flank of female NMRI nu/nu mice (18-21 g, 5-6 weeks). For the AML model in rats, 2×106 MV4-11 human AML cells are inoculated subcutaneously to the left flank of female athymic nude rats (160-200 g, 5-6 weeks). Animals are stratified into treatment and control groups (n=8-13/group for mice, n=12/group for rats) based on primary tumor size. Treatments are started 3-13 days after tumor cell inoculation when the average tumor sizes are 23-38 mm2 and 43 mm2 for mice and rats, respectively. The 20 and 25 mg/kg once daily dose is for nude mice. Furthermore, Atuveciclib (BAY-1143572) administered at 25 or 35 mg/kg, three days on/two days off. BAY-1143572 is administered daily oral administration of Atuveciclib (BAY-1143572) at 12 mg/kg for rats. Unless otherwise indicated, all treatments are administered orally (p.o.) and are continued until the end of the experiment. Body weight and tumor areas (longest diameter multiplied by its perpendicular) measured by caliper are determined at least twice weekly. T/C ratios are calculated by dividing the mean tumor area of the treatment group by the mean tumor area of the vehicle group at the time point when the vehicle group is sacrificed[1].

References:

[1]. Lücking U, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017 Nov 8;12(21):1776-1793.